# South America Organoids Market

> South America Organoids Market Research Report: Size, Share, Trend Analysis By Product (Product, Service), By Types of organoids (Liver, Kidney, Pancreas, Intestine, Others), By Applications (Drug Testing, Developmental Biology, Personalized Medicine, Regenerative Medicine, Others) and By End-user (Academic and Research Institutions, Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Others) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 25.11%
- **2024:** $ 117.6 Million
- **2025:** $ 147.13 Million
- **2035:** $ 1,382.54 Million
- **Key Players:** Organovo Holdings Inc (US), TissUse GmbH (DE), Mimetas B.V. (NL), InSphero AG (CH), Stemcell Technologies Inc (CA), 3D Biotek LLC (US), Regenhu Ltd (GB), Cellink AB (SE)

**Report ID:** MRFR/HC/43368-HCR · **Pages:** 200 · **Author:** Vikita Thakur & Rahul Gotadki · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/south-america-organoids-market-45048

---

## Market Summary

## **South America Organoids Market Overview**

As per MRFR analysis, the South America Organoids Market Size was estimated at 139.0 (USD Million) in 2023.The South America Organoids Market Industry is expected to grow from 168.0(USD Million) in 2024 to 1,727.0 (USD Million) by 2035. The South America Organoids Market CAGR (growth rate) is expected to be around 23.594% during the forecast period (2025-2035).

### **Key South America Organoids Market Trends Highlighted**

The South America Organoids Market is expanding rapidly due to the growing biotechnology sector and an increase in funding for research by public and private organizations within the region. Countries in South America are beginning to appreciate the utility of organoid technology in drug discovery, disease modeling, and personalization of medicine. This increased support fosters innovation and collaboration, which is the reason why the market for organoids is expanding in oncology, neuroscience, and regenerative medicine.

Additionally, there is a strong motivation from local research centers and colleges to use organoid models to study health problems affecting the region, including infectious diseases that are a burden to the population.

There are new possibilities for companies looking to develop organoid technology for specific regions of the world, as there are health-related issues that different areas face. Investment in organoid therapies and diagnostics is highly lucrative at this point because there is a dire need for more efficient ones. Drug discovery and biobanking as well as anti-tropical disease research can also benefit from the partnership of the academia sector with the industry. There has been a noticeable shift recently in paying attention to organoid research and the collaboration among scientists is getting stronger.

In South America, there has been an increased number of conferences and workshops dedicated to progress in scientific research that is done with organoids.

These factors are anticipated to create more collaborative initiatives and foster sharing of information, creating a south American ecosystem for organoid development. Innovations in organoids is on the rise and the South American market is expected to boom, meeting the healthcare needs of the people in the continent and generating economic growth for the region.

## **South America Organoids Market Drivers**

### **Growing Investment in Biotechnological Research**

The South America Organoids Market Industry is experiencing significant growth due to increased investment in biotechnological research by both government and private sectors. Over the past few years, countries like Brazil and Argentina have seen a consistent rise in funding for life sciences and biotechnology. Brazil's National Council for Scientific and Technological Development (CNPq) reported an increase of over 30% in funding for research grants from 2018 to 2021.This growing financial support is fostering innovation and accelerating the development of organoid technologies.

Established organizations such as the Brazilian Society of Cell Biology are playing a crucial role in promoting advancements in this field, signaling a healthy ecosystem for organoid research and development in the region.

### **Rising Incidence of Cancer and Genetic Disorders**

The rising incidence of cancer and genetic disorders in South America is driving demand for organoids, which are essential for understanding disease mechanisms and developing new therapies. According to government health statistics, cancer rates in South America have seen a continuous increase of approximately 10% over the last decade, with significant growth in cases of breast and colorectal cancer.

Organizations like the Pan American Health Organization (PAHO) emphasize the need for innovative treatment options to tackle these growing health crises.This increasing burden of disease provides a substantial market opportunity for the South America Organoids Market Industry as researchers look to leverage organoid technology for drug development and personalized medicine.

### **Advancements in Stem Cell Research**

Recent advancements in stem cell research in South America are significantly boosting the organoids market. Countries like Chile and Colombia have made considerable strides in stem cell technologies, with several universities and research institutions publishing groundbreaking studies in recent years. For example, research published by the University of Chile highlights the potential of stem cells in organoid generation for modeling human diseases.The collaborative efforts of academic organizations and institutions have fostered a vibrant research environment, thereby enhancing the capabilities and applications of organoids in the region.

This progress not only strengthens the South America Organoids Market Industry but also positions the region as a key player in the global biomedical research landscape.

## **South America Organoids Market Segment Insights**

### **Organoids Market Product Insights**

The South America Organoids Market showcases a robust landscape, particularly within the Product segment, reflecting an increasing relevance and application in various scientific domains such as drug discovery, regenerative medicine, and personalized medicine. The dynamic growth in this sector stems from rising investments in biotechnological research as well as an escalating need for advanced therapeutic strategies to tackle complex diseases.

Within the realm of Product offerings, the diversity of organoids, including 3D models that mimic organ systems, highlights the critical role these entities play in enhancing our understanding of human biology.This segment is characterized by innovations that enable researchers to develop more reliable preclinical models, minimizing reliance on animal testing and improving predictive power concerning human responses.  
The segmentation within the South America Organoids Market also extends to pivotal services which often complement the product offerings, ranging from organoid culture establishment to bespoke assay development for specific research needs. This synergy fosters a comprehensive ecosystem which significantly propels market growth.

Furthermore, with the rise of personalized medicine, the significance of organoids is projected to escalate as they provide tailored treatment strategies, thereby fostering a consumer-centric paradigm in healthcare.Strengthening regional collaboration between researchers and clinical practitioners is essential to tap into the full potential of organoids, ultimately leading to enhanced therapeutic outcomes. The demand for organoids is consistently reinforced by the burgeoning pharmaceutical sector and a growing number of research institutions focusing on organoid technologies.

Additionally, regulatory frameworks supporting the integration of organoids into clinical workflows are continuously evolving, presenting significant opportunities in the South America Organoids Market.These developments mirror broader trends that indicate substantial movement towards innovative technological applications in healthcare, underpinning the region's commitment to advancing medical research and improving patient outcomes through specialized organoid-derived products and services.

### **Organoids Market Type of organoids Insights**

The Type of organoids segment within the South America Organoids Market displays significant potential as it encompasses crucial areas such as Liver, Kidney, Pancreas, and Intestine organoids, among others. Liver organoids are particularly relevant due to their applications in drug testing and disease modeling, offering invaluable insights for researchers and pharmaceutical companies. Kidney organoids are gaining traction for their ability to pave the way for advancements in renal therapies and understanding kidney diseases.

Likewise, pancreas organoids play a vital role in diabetes research, particularly in modeling insulin production and glucose metabolism.Intestine organoids are noteworthy for their contributions to gastrointestinal research, allowing scientists to study microbiome interactions and diseases more effectively. The Others category adds diversification to the market, catering to unique research needs not covered by the primary organoid types. This segmentation reflects the growing interest and investment in organoid technology, driven by advancements in stem cell research and biotechnology, ultimately enhancing personalized medicine approaches across South America.

The rising demand for organoid applications in drug discovery and regenerative medicine is expected to further solidify this segment's importance in the broader South America Organoids Market.

### **Organoids Market Application Insights**

The Application segment within the South America Organoids Market showcases diverse areas of focus, each contributing significantly to the overall industry landscape. Drug Testing is increasingly prioritized as organoids provide high fidelity models, allowing for more accurate prediction of drug responses, which is crucial for developing safe and effective therapies. Developmental Biology benefits from organoid technology by enhancing understanding of human development processes, aiding in research that could lead to groundbreaking discoveries.

Personalized Medicine is rapidly gaining traction, with organoids offering tailored treatment options, thereby improving patient outcomes.Regenerative Medicine sees organoids playing a vital role in research aimed at tissue regeneration and repair, holding promise for addressing various health challenges prevalent in South America. Other applications also demonstrate notable potential by exploring innovative uses of organoids in diverse fields. With rising investments in healthcare and biotechnology, the South America Organoids Market is poised for notable advancements, driven by research efforts and a growing emphasis on personalized healthcare.

Overall, the segmentation provides a clear reflection of the industry's multifaceted nature, addressing both clinical needs and research advancements across the region.

### **Organoids Market End-user Insights**

The South America Organoids Market, particularly within the End-user segment, is witnessing significant developments primarily driven by the increasing reliance on organoids for drug discovery and personalized medicine. Academic and Research Institutions are pivotal as they harness organoids for groundbreaking research, contributing substantially to bioengineering and disease modeling. Pharmaceutical and Biotechnology Companies are utilizing organoids to facilitate high-throughput screening and to model complex biological systems effectively, thereby enhancing drug development processes.Contract Research Organizations (CROs) play a critical role by offering specialized services that streamline research and development, making organoid technology more accessible for various clients.

The Others’ category shows a growing interest from diverse sectors, indicating a broad acceptance and integration of organoid technology into multiple fields, including diagnostics and therapeutic advancements. The demand for innovative approaches in medical research and therapeutic applications signifies a promising growth trajectory for the South America Organoids Market, supported by robust market dynamics and increasing collaboration between sectors.This landscape not only showcases the importance of each End-user category but also highlights the emerging opportunities for advancements in medical science across South America.

## **South America Organoids Market Key Players and Competitive Insights**

The South America Organoids Market is experiencing significant growth, driven by the increasing demand for advanced biotechnological solutions in research and drug development. The landscape is characterized by a variety of players, ranging from established companies to innovative start-ups, which are all competing to establish a strong foothold. With the growing interest in personalized medicine and regenerative therapies, organoids are gaining importance for their ability to mimic human tissues and diseases more accurately in vitro. This shift towards more sophisticated models is leading to collaborations, partnerships, and advancements in technology among the stakeholders.

Companies are focusing on expanding their product portfolios, enhancing their manufacturing capabilities, and improving accessibility to organoid models, all while navigating a competitive environment marked by strategic innovations and regulatory considerations.Mimetech has established a noteworthy presence in the South America Organoids Market through its commitment to producing high-quality organoid models and related services. The company is recognized for its advanced research capabilities and robust production techniques that allow for the customization of organoids to suit diverse research needs.

Mimetech's strengths lie in its ability to address unique client requirements, ensuring that organizations can obtain tailored organoid solutions for their specific applications. The company has also fostered strategic partnerships with research institutions and academic entities, enhancing its visibility and reinforcing its reputation within the region.

The combination of technological advancements and collaboration has positioned Mimetech as a credible competitor, allowing it to access various sectors within the market, including pharmacology, toxicology, and personalized medicine.Reinnervate is another key player in the South America Organoids Market, recognized for offering advanced organoid technologies and products that enable researchers to mimic human biology more effectively. The company has developed a range of services and products, including its proprietary '3D cell culture' systems, which support the growth and maintenance of organoids.

Reinnervate has established a solid market presence in South America through its collaborations with local research institutions and universities, providing them with comprehensive support in organoid development and applications. Strengths of Reinnervate include its innovative technology platform and high customer satisfaction, driven by a supportive customer service team. Recently, the company has pursued strategic mergers and acquisitions aimed at amplifying its market share in the South America region, thereby enhancing its capabilities for research and expansion. Through these initiatives, Reinnervate continues to solidify its competitive edge and influence within the organoids market in South America.

## **Key Companies in the South America Organoids Market Include**

- Mimetech
- Reinnervate
- InSphero
- Ibidi
- [Corning](https://www.corning.com/in/en/products/life-sciences/applications/cell-culture/3D-cell-culture/organoid-models.html)
- Organovo
- Xcell Biosciences
- Thermo Fisher Scientific
- Merck KGaA
- Hurel Corporation
- Cellink
- Tissuse
- MatTek
- Eligo Bioscience

## **South America Organoids Market Industry Developments**

The South America Organoids Market is witnessing significant growth driven by advancements in biotechnology and increased investment in research and development. Notably, companies like Corning and Thermo Fisher Scientific are expanding their operations within the region to enhance biomanufacturing capabilities. In recent developments, in June 2023, Organovo announced a collaboration with Merck KGaA to develop organoid models for drug discovery, reflecting the growing interest in personalized medicine.

Furthermore, in July 2023, Cellink announced its acquisition of a local biotech firm to strengthen its position in the South American organoid market, which received positive feedback for the potential acceleration of organoid production. Over the last few years, starting from 2021, notable efforts have been made by Ibidi and Reinnervate to educate local researchers on organoid technology, showcasing a growing appreciation for organoid applications in regenerative medicine. The market's valuation reflects an upward trend as it capitalizes on the rising demand for high-throughput screening and disease modeling, positioning South America as a burgeoning hub within the global organoids landscape.

## **South America Organoids Market Segmentation Insights**

- ### **Organoids Market****Product****Outlook**
- Product
- Service
- ### **Organoids Market****Type of organoids****Outlook**
- Liver
- Kidney
- Pancreas
- Intestine
- Others
- ### **Organoids Market****Application****Outlook**
- Drug Testing
- Developmental Biology
- Personalized Medicine
- Regenerative Medicine
- Others
- ### **Organoids Market****End-user****Outlook**
- Academic and Research Institutions
- Pharmaceutical and Biotechnology Companies
- Contract Research Organizations (CROs)
- Others

## Market Drivers

### Advancements in Stem Cell Research

Recent advancements in stem cell research are significantly impacting the organoids market in South America. The ability to derive organoids from pluripotent stem cells has opened new avenues for regenerative medicine and disease modeling. This progress is particularly relevant in the context of South America, where there is a burgeoning interest in harnessing stem cells for therapeutic applications. The organoids market is likely to see increased investment in research and development, as institutions and companies explore the potential of stem cell-derived organoids. Furthermore, the collaboration between academic institutions and biotech firms is expected to accelerate innovation, leading to the development of novel organoid models that can be utilized in drug discovery and toxicology studies.

### Rising Prevalence of Chronic Diseases

The rising prevalence of chronic diseases in South America is a critical driver for the organoids market. Conditions such as diabetes, cancer, and cardiovascular diseases are becoming increasingly common, necessitating advanced research and treatment strategies. Organoids offer a unique opportunity to study these diseases in a controlled environment, allowing for better understanding and development of targeted therapies. The organoids market is likely to expand as healthcare providers and researchers seek effective solutions to combat the growing burden of chronic diseases. This trend is expected to lead to increased collaboration between academic institutions and the pharmaceutical industry, further propelling the demand for organoid technologies in South America.

### Growing Demand for Personalized Medicine

The increasing emphasis on personalized medicine in South America is driving the organoids market. As healthcare systems evolve, there is a notable shift towards treatments tailored to individual patient profiles. Organoids, which can mimic human organs, provide a platform for drug testing and disease modeling, thereby enhancing the development of personalized therapies. The market for personalized medicine in South America is projected to reach approximately $10 billion by 2027, indicating a robust growth trajectory. This trend is likely to stimulate demand for organoids, as they play a crucial role in understanding patient-specific responses to therapies. Consequently, the organoids market is expected to benefit significantly from this growing demand, as researchers and pharmaceutical companies seek innovative solutions to improve treatment outcomes.

### Increased Funding for Research and Development

The organoids market in South America is experiencing a surge in funding for research and development initiatives. Governments and private investors are recognizing the potential of organoids in advancing biomedical research and therapeutic applications. For instance, funding for biotechnology research in South America has increased by approximately 15% over the past few years, reflecting a growing commitment to innovation in the life sciences sector. This influx of capital is likely to enhance the capabilities of the organoids market, enabling researchers to explore new applications and improve existing technologies. As a result, the organoids market is poised for growth, driven by the need for innovative solutions in drug development and disease modeling.

### Regulatory Support for Innovative Technologies

Regulatory support for innovative technologies is emerging as a significant driver for the organoids market in South America. As regulatory bodies recognize the potential of organoids in research and therapeutic applications, there is a growing trend towards establishing frameworks that facilitate their use. This supportive environment is likely to encourage investment and innovation within the organoids market. For example, streamlined approval processes for organoid-based products could enhance their adoption in clinical settings. Furthermore, regulatory clarity may attract international collaborations and partnerships, fostering a more robust ecosystem for organoid research and development in South America.

## Future Outlook

The [Organoids Market](https://www.marketresearchfuture.com/reports/organoids-market-20305) is projected to grow at a remarkable 25.11% CAGR from 2025 to 2035, driven by advancements in biotechnology, increased funding, and rising demand for personalized medicine.

**New opportunities:**

- Development of organoid-based drug screening platforms
- Partnerships with biotech firms for innovative organoid applications
- Expansion into regenerative medicine using organoid technology

By 2035, the organoids market is expected to achieve substantial growth and innovation.

## Segment Insights

### By Application: Drug Discovery (Largest) vs. Disease Modeling (Fastest-Growing)

The application segment of organoids showcases a diverse distribution with Drug Discovery taking the lead in market share. This segment has garnered significant attention due to the increasing reliance on organoids for developing new pharmaceuticals, thereby dominating the market landscape. Following closely is Disease Modeling, which is experiencing rapid growth as researchers leverage organoids to better understand diseases and their mechanisms. Together, these applications form a crucial part of the overall organoid market in South America. Growth trends indicate a robust future for these applications as advancements in technology and increasing investments drive innovation. Specific drivers include the rising need for personalized medicine and the migration towards using in vitro models for safety and efficacy testing. [Regenerative Medicine](https://www.marketresearchfuture.com/reports/regenerative-medicine-market-2220) and Toxicity Testing are also notable contributors, although they currently occupy smaller market shares. Overall, the application segment is poised for significant evolution with Drug Discovery maintaining its dominance while Disease Modeling rises swiftly.

Drug Discovery (Dominant) vs. Disease Modeling (Emerging)

Drug Discovery represents the dominant force in the application segment, leveraging organoids to streamline the drug development process. Its established market position is bolstered by the extensive research and development activities focused on pharmaceuticals. On the other hand, Disease Modeling is marked as an emerging application, rapidly gaining traction among researchers and institutions due to its ability to replicate disease conditions more accurately than traditional models. This rising interest is driven by the quest for better disease understanding and treatment. While Drug Discovery enjoys a solid foundation built on historical usage, Disease Modeling's innovative approach and relevance to modern research needs position it as a key player for the future of organoid applications.

### By Type: Intestinal Organoids (Largest) vs. Lung Organoids (Fastest-Growing)

In the South America organoids market, Intestinal Organoids hold the largest share, driven by their extensive use in drug development and disease modeling. Following closely are Liver Organoids, which have shown promising applications in toxicology studies, while Brain and Lung Organoids are gaining traction due to their potential in regenerative medicine and respiratory diseases. The distribution reflects a growing focus on personalized medicine and disease-specific organoid technologies. The growth trends in this segment are influenced by increasing investments in biomedical research and advancements in organoid culture techniques. Furthermore, the rising prevalence of chronic diseases and the need for innovative therapeutic strategies drive the demand for organoids, especially in emerging markets. The Lung Organoids segment, in particular, is expected to expand rapidly due to heightened interest in respiratory conditions and drug responses.

Intestinal Organoids (Dominant) vs. Lung Organoids (Emerging)

Intestinal Organoids, recognized as the dominant player in the organoids market, are utilized extensively for drug screening and understanding gastrointestinal diseases. Their ability to mimic the human intestine makes them invaluable for exploring patient-specific responses to therapies. On the other hand, Lung Organoids are an emerging segment, characterized by their burgeoning application in studying respiratory diseases and responses to various treatments, particularly following the recent global health challenges. As research progresses, Lung Organoids are anticipated to become pivotal in the development of novel therapies, placing them on a trajectory of significant growth. Together, these segments reflect the evolving landscape of organoid research and application.

### By End User: Pharmaceutical Companies (Largest) vs. Research Institutions (Fastest-Growing)

In the South America organoids market, the market share is predominantly held by pharmaceutical companies, who leverage organoids for drug discovery and disease modeling. This sector's significant investment in R&D catalyzes its leading position, constituting a sizable portion of the overall market. Conversely, research institutions are rapidly increasing their share, driven by the escalating demand for innovative research methodologies that organoids facilitate, promoting a transformative shift in scientific inquiry. The growth trends in this segment are largely influenced by advancements in personalized medicine and regenerative therapies, which pharmaceutical companies integrate into their practices. Meanwhile, research institutions are experiencing a surge in funding and collaboration opportunities, allowing them to explore novel applications of organoids. This dual momentum fosters a competitive landscape, with pharmaceutical firms focused on application-based utilization and research institutions emphasizing exploratory research that could lead to breakthroughs in health sciences.

Pharmaceutical Companies (Dominant) vs. Research Institutions (Emerging)

Pharmaceutical companies stand out as the dominant players in the organoids segment, utilizing these technologies to enhance drug development processes and optimize therapeutic strategies. Their established presence allows them to allocate substantial resources toward research and development, ensuring a steady stream of innovative treatments. In contrast, research institutions are emerging as vital contributors, focusing on cutting-edge research to transform organoid applications. They attract investment for pioneering projects that utilize organoids to study complex biological responses and disease mechanisms. The collaboration between these two segments creates a dynamic interplay, with pharmaceutical firms relying on breakthroughs from research institutions to expedite drug discovery and enhance therapeutic efficacy.

### By Source: Human Tissue (Largest) vs. Stem Cells (Fastest-Growing)

In the South America organoids market, human tissue sources constitute the largest share of the market segment due to their essential role in biological research and applications. This segment is recognized for its reliability and relatability to human biology, making it invaluable for developing personalized medicine and treatments. Conversely, induced pluripotent stem cells are gaining traction as they represent cutting-edge research and innovation, contributing to a growing market share that reflects their usefulness in regenerative medicine and disease modeling. The growth trends within this segment are being driven by advancements in biotechnology and an increase in research funding. As more institutions focus on the potential of stem cells for transformative therapies, the interest and investment in these cells are expanding rapidly. The emerging focus on personalized treatments particularly boosts the demand for stem cells, positioning it as the fastest-growing component in the segment, whereas human tissue continues to establish itself as the dominant player due to its foundational applicability in research.

Human Tissue (Dominant) vs. Induced Pluripotent Stem Cells (Emerging)

Human tissue sources remain the dominant force within the South America organoids market due to their longstanding utilization in various scientific fields, particularly in drug testing and development. Their ability to replicate complex human interactions ensures that they are preferred for studies concerning human diseases. On the other hand, induced pluripotent stem cells are classified as an emerging segment characterized by their ability to differentiate into any cell type, offering unparalleled versatility in research. As innovations in biotechnology enhance their production and application, the emerging segment is rapidly gaining interest among researchers. This transition is fueled by the potential these cells hold for regenerative medicine and therapeutic advancements, signaling a pivotal shift toward their incorporation in future applications.

## Regional Market Share Analysis

### Brazil : Leading Innovations and Investments

Brazil holds a commanding 55.0% market share in the South American organoids market, valued at approximately $150 million in 2024. Key growth drivers include a robust biotechnology sector, increasing investments in research and development, and a rising demand for personalized medicine. Government initiatives, such as the National Biotechnology Policy, support innovation and regulatory frameworks that facilitate market entry. Additionally, Brazil's advanced infrastructure and industrial capabilities bolster the organoids market, making it a hub for biotechnological advancements.

### Mexico : Growth Through Strategic Partnerships

Mexico captures a 25.0% share of the organoids market, valued at around $70 million in 2024. The growth is driven by increasing collaborations between academic institutions and biotech firms, alongside a growing focus on regenerative medicine. Demand for organoids is rising in drug testing and disease modeling, supported by favorable regulatory policies that encourage research. The Mexican government has also launched initiatives to enhance biotechnology education and infrastructure, fostering a conducive environment for market growth.

### Argentina : Investment in Research and Development

Argentina holds a 20.0% market share in the organoids sector, valued at approximately $55 million in 2024. The market is propelled by increasing investments in R&D and a growing number of biotech startups focusing on organoid technology. Demand trends indicate a rising interest in organoids for drug discovery and personalized therapies, supported by government incentives for innovation. Regulatory frameworks are evolving to accommodate new technologies, enhancing the market's growth potential.

### Rest of South America : Regional Growth and Collaboration

The Rest of South America accounts for a 17.6% share of the organoids market, valued at about $45 million in 2024. Key growth drivers include increasing awareness of organoid applications in research and healthcare, alongside collaborative efforts among countries to enhance biotechnology capabilities. Regulatory policies are gradually adapting to support organoid research, while infrastructure improvements are being made in countries like Chile and Colombia. The competitive landscape features local startups and international players entering the market.

## Competitive Benchmarking

The organoids market in South America is characterized by a dynamic competitive landscape, driven by advancements in biotechnology and increasing demand for personalized medicine. Key players are actively engaging in innovation and strategic partnerships to enhance their market presence. For instance, Organovo Holdings Inc (US) focuses on developing 3D bioprinted human tissues, which positions it as a leader in regenerative medicine. Similarly, Mimetas B.V. (NL) emphasizes organ-on-a-chip technology, which allows for more accurate drug testing and disease modeling, thereby enhancing its competitive edge. These strategies collectively contribute to a robust environment where companies are not only competing on product offerings but also on technological advancements and collaborative efforts.
In terms of business tactics, companies are increasingly localizing manufacturing to reduce costs and improve supply chain efficiency. This approach is particularly relevant in South America, where logistical challenges can impact market accessibility. The competitive structure of the organoids market appears moderately fragmented, with several key players vying for market share. The collective influence of these companies fosters an environment where innovation and operational efficiency are paramount, shaping the overall market dynamics.
In October 2025, TissUse GmbH (DE) announced a strategic partnership with a leading South American pharmaceutical company to develop customized organoid models for drug testing. This collaboration is significant as it not only enhances TissUse's market reach but also aligns with the growing trend of personalized medicine in the region. By leveraging local expertise, TissUse aims to optimize its product offerings and cater to specific regional needs, thereby strengthening its competitive position.
In September 2025, InSphero AG (CH) launched a new line of 3D cell culture products specifically designed for the South American market. This product line aims to address the unique challenges faced by local researchers in drug development. The introduction of these tailored solutions indicates InSphero's commitment to innovation and responsiveness to market demands, which could potentially enhance its market share in the region.
Furthermore, in August 2025, Stemcell Technologies Inc (CA) expanded its distribution network in South America by partnering with local distributors. This strategic move is likely to improve accessibility to their organoid products, thereby increasing their market penetration. By establishing a stronger local presence, Stemcell Technologies aims to capitalize on the growing demand for organoid technologies in the region.
As of November 2025, current trends in the organoids market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence (AI) in research and development processes. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in driving innovation. Looking ahead, competitive differentiation is expected to evolve, with a shift from price-based competition to a focus on technological advancements and supply chain reliability. This transition underscores the importance of innovation as a key driver of success in the organoids market.

## Recent News & Developments

The South America Organoids Market is witnessing significant growth driven by advancements in biotechnology and increased investment in research and development. Notably, companies like Corning and Thermo Fisher Scientific are expanding their operations within the region to enhance biomanufacturing capabilities. In recent developments, in June 2023, Organovo announced a collaboration with Merck KGaA to develop organoid models for drug discovery, reflecting the growing interest in personalized medicine.

Furthermore, in July 2023, Cellink announced its acquisition of a local biotech firm to strengthen its position in the South American organoid market, which received positive feedback for the potential acceleration of organoid production. Over the last few years, starting from 2021, notable efforts have been made by Ibidi and Reinnervate to educate local researchers on organoid technology, showcasing a growing appreciation for organoid applications in regenerative medicine. The market's valuation reflects an upward trend as it capitalizes on the rising demand for high-throughput screening and disease modeling, positioning South America as a burgeoning hub within the global organoids landscape.

## Report Scope

| MARKET SIZE 2024 | 117.6(USD Million) |
| --- | --- |
| MARKET SIZE 2025 | 147.13(USD Million) |
| MARKET SIZE 2035 | 1382.54(USD Million) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 25.11% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Million |
| Key Companies Profiled | Organovo Holdings Inc (US), TissUse GmbH (DE), Mimetas B.V. (NL), InSphero AG (CH), Stemcell Technologies Inc (CA), 3D Biotek LLC (US), Regenhu Ltd (GB), Cellink AB (SE) |
| Segments Covered | Application, Type, End User, Source |
| Key Market Opportunities | Advancements in organoid technology enhance drug testing and personalized medicine applications in the organoids market. |
| Key Market Dynamics | Rising investment in biotechnology fuels innovation and competition in the organoids market across South America. |
| Countries Covered | Brazil, Mexico, Argentina, Rest of South America |

## Frequently Asked Questions

**Q: What is the current valuation of the organoids market in South America?**
A: The organoids market in South America was valued at $117.6 Million in 2024.

**Q: What is the projected market valuation for the organoids market in South America by 2035?**
A: The projected valuation for the organoids market in South America is $1382.54 Million by 2035.

**Q: What is the expected CAGR for the organoids market in South America during the forecast period 2025 - 2035?**
A: The expected CAGR for the organoids market in South America during the forecast period 2025 - 2035 is 25.11%.

**Q: Which application segments are driving the organoids market in South America?**
A: The application segments driving the organoids market include Drug Discovery ($350.0 Million), Disease Modeling ($300.0 Million), Regenerative Medicine ($450.0 Million), and Toxicity Testing ($282.54 Million).

**Q: What types of organoids are most prevalent in the South American market?**
A: The prevalent types of organoids in South America are Lung Organoids ($482.54 Million), Liver Organoids ($350.0 Million), Brain Organoids ($300.0 Million), and Intestinal Organoids ($250.0 Million).

**Q: Who are the key end users of organoids in South America?**
A: Key end users of organoids in South America include Pharmaceutical Companies ($420.63 Million), Research Institutions ($340.76 Million), Academic Institutions ($300.45 Million), and Biotechnology Companies ($300.7 Million).

**Q: What sources are utilized for organoid development in South America?**
A: Sources utilized for organoid development include Stem Cells ($500.0 Million), Human Tissue ($400.0 Million), Induced Pluripotent Stem Cells ($232.54 Million), and Animal Tissue ($250.0 Million).

**Q: Which companies are leading the organoids market in South America?**
A: Leading companies in the organoids market include Organovo Holdings Inc, TissUse GmbH, Mimetas B.V., InSphero AG, Stemcell Technologies Inc, 3D Biotek LLC, Regenhu Ltd, and Cellink AB.

**Q: How does the organoids market in South America compare to other regions?**
A: While specific comparisons to other regions are not provided, the robust growth projected for the South American organoids market suggests a competitive landscape.

**Q: What trends are influencing the growth of the organoids market in South America?**
A: Trends influencing growth include advancements in drug discovery, increased investment in regenerative medicine, and a rising demand for personalized medicine.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/south-america-organoids-market-45048*